Publication details
- Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts (Julia Pöschl, Sebastian Stark, Philipp Neumann, Susanne Gröbner, Daisuke Kawauchi, David T.W. Jones, Paul A. Northcott, Peter Lichter, Stefan M. Pfister, Marcel Kool, Ulrich Schüller), In Acta Neuropathologica, Series: 128(1), pp. 123–136, (Editors: Werner Paulus), Springer, ISSN: 0001-6322, 2014
Publication details – DOI
Abstract
Medulloblastoma is a malignant embryonal brain tumor with highly variable outcome. In order to study the biology of this tumor and to perform preclinical treatment studies, a lot of effort has been put into the generation of appropriate mouse models. The usage of these models, however, has become debatable with the advances in human medulloblastoma subgrouping. This study brings together multiple relevant mouse models and matches genetic alterations and gene expression data of 140 murine tumors with 423 human medulloblastomas in a global way. Using AGDEX analysis and k-means clustering, we show that the Blbp-cre::Ctnnb1(ex3)Fl/+Trp53Fl/Fl mouse model fits well to human WNT medulloblastoma, and that, among various Myc- or Mycn-based mouse medulloblastomas, tumors in Glt1-tTA::TRE-MYCN/Luc mice proved to be most specific for human group 3 medulloblastoma. None of the analyzed models displayed a significant match to group 4 tumors. Intriguingly, mice with Ptch1 or Smo mutations selectively modeled SHH medulloblastomas of adulthood, although such mutations occur in all human age groups. We therefore suggest that the infantile or adult gene expression pattern of SHH MBs are not solely determined by specific mutations. This is supported by the observation that human medulloblastomas with PTCH1 mutations displayed more similarities to PTCH1 wild-type tumors of the same age group than to PTCH1-mutated tumors of the other age group. Together, we provide novel insights into previously unrecognized specificity of distinct models and suggest these findings as a solid basis to choose the appropriate model for preclinical studies on medulloblastoma.
BibTeX
@article{GATAMMMMTT14, author = {Julia Pöschl and Sebastian Stark and Philipp Neumann and Susanne Gröbner and Daisuke Kawauchi and David T.W. Jones and Paul A. Northcott and Peter Lichter and Stefan M. Pfister and Marcel Kool and Ulrich Schüller}, title = {{Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts}}, year = {2014}, editor = {Werner Paulus}, publisher = {Springer}, journal = {Acta Neuropathologica}, series = {128(1)}, pages = {123--136}, issn = {0001-6322}, doi = {http://dx.doi.org/10.1007/s00401-014-1297-8}, abstract = {Medulloblastoma is a malignant embryonal brain tumor with highly variable outcome. In order to study the biology of this tumor and to perform preclinical treatment studies, a lot of effort has been put into the generation of appropriate mouse models. The usage of these models, however, has become debatable with the advances in human medulloblastoma subgrouping. This study brings together multiple relevant mouse models and matches genetic alterations and gene expression data of 140 murine tumors with 423 human medulloblastomas in a global way. Using AGDEX analysis and k-means clustering, we show that the Blbp-cre::Ctnnb1(ex3)Fl/+Trp53Fl/Fl mouse model fits well to human WNT medulloblastoma, and that, among various Myc- or Mycn-based mouse medulloblastomas, tumors in Glt1-tTA::TRE-MYCN/Luc mice proved to be most specific for human group 3 medulloblastoma. None of the analyzed models displayed a significant match to group 4 tumors. Intriguingly, mice with Ptch1 or Smo mutations selectively modeled SHH medulloblastomas of adulthood, although such mutations occur in all human age groups. We therefore suggest that the infantile or adult gene expression pattern of SHH MBs are not solely determined by specific mutations. This is supported by the observation that human medulloblastomas with PTCH1 mutations displayed more similarities to PTCH1 wild-type tumors of the same age group than to PTCH1-mutated tumors of the other age group. Together, we provide novel insights into previously unrecognized specificity of distinct models and suggest these findings as a solid basis to choose the appropriate model for preclinical studies on medulloblastoma.}, }